At a median follow-up of 8.7 months, the average progression-free survival, which is the time from treatment until disease worsens, was 5.8 months in the Rivoceranib group, compared with 3.3 months ...

Patti Drinville, President/CEO, The PLD Group Inc. in Thousand Palms Calif., talks about the work that her company produces - statement processing and undeliverable mail needs from the simple to ...

The safety analysis included all 53 patients enrolled in the trial. Treatment-related adverse events (TRAEs) occurred in 18 (78.3%) patients in the paclitaxel group and 19 (63.3%) of the PLD group.

In the GEM or PLD group, neutrophil count decreased was the most common grade 3 or 4 TRAE, occurring in 62 patients (40.0%), compared with one patient in the nivolumab group (0.6%). irAEs (any grade) ...